Elevated Fibronectin Levels in Profibrotic CD14+ Monocytes and CD14+ Macrophages in Systemic Sclerosis by Rudnik, Michał et al.








Elevated Fibronectin Levels in Profibrotic CD14+ Monocytes and CD14+
Macrophages in Systemic Sclerosis
Rudnik, Michał ; Hukara, Amela ; Kocherova, Ievgeniia ; Jordan, Suzana ; Schniering, Janine ; Milleret,
Vincent ; Ehrbar, Martin ; Klingel, Karin ; Feghali-Bostwick, Carol ; Distler, Oliver ; Błyszczuk,
Przemysław ; Kania, Gabriela
Abstract: Background: Systemic sclerosis (SSc) is an autoimmune disease characterized by overproduc-
tion of extracellular matrix (ECM) and multiorgan fibrosis. Animal studies pointed to bone marrow-
derived cells as a potential source of pathological ECM-producing cells in immunofibrotic disorders. So
far, involvement of monocytes and macrophages in the fibrogenesis of SSc remains poorly understood.
Methods and results: Immunohistochemistry analysis showed accumulation of CD14+ monocytes in the
collagen-rich areas, as well as increased amount of alpha smooth muscle actin (฀SMA)-positive fibroblasts,
CD68+ and mannose-R+ macrophages in the heart and lungs of SSc patients. The full genome tran-
scriptomics analyses of CD14+ blood monocytes revealed dysregulation in cytoskeleton rearrangement,
ECM remodeling, including elevated FN1 (gene encoding fibronectin) expression and TGF-฀ signalling
pathway in SSc patients. In addition, single cell RNA sequencing analysis of tissue-resident CD14+
pulmonary macrophages demonstrated activated profibrotic signature with the elevated FN1 expression
in SSc patients with interstitial lung disease. Peripheral blood CD14+ monocytes obtained from either
healthy subjects or SSc patients exposed to profibrotic treatment with profibrotic cytokines TGF-฀, IL-
4, IL-10, and IL-13 increased production of type I collagen, fibronectin, and ฀SMA. In addition, CD14+
monocytes co-cultured with dermal fibroblasts obtained from SSc patients or healthy individuals acquired
a spindle shape and further enhanced production of profibrotic markers. Pharmacological blockade of
the TGF-฀ signalling pathway with SD208 (TGF-฀ receptor type I inhibitor), SIS3 (Smad3 inhibitor) or
(5Z)-7-oxozeaenol (TGF-฀-activated kinase 1 inhibitor) ameliorated fibronectin levels and type I collagen
secretion. Conclusions: Our findings identified activated profibrotic signature with elevated production of
profibrotic fibronectin in CD14+ monocytes and CD14+ pulmonary macrophages in SSc and highlighted
the capability of CD14+ monocytes to acquire a profibrotic phenotype. Taking together, tissue-infiltrating
CD14+ monocytes/macrophages can be considered as ECM producers in SSc pathogenesis. Keywords:
CD14+ macrophages; CD14+ monocytes; TGF-฀; fibronectin; fibrosis; systemic sclerosis.
DOI: https://doi.org/10.3389/fimmu.2021.642891






The following work is licensed under a Creative Commons: Attribution 4.0 International (CC BY 4.0)
License.
Originally published at:
Rudnik, Michał; Hukara, Amela; Kocherova, Ievgeniia; Jordan, Suzana; Schniering, Janine; Milleret,
Vincent; Ehrbar, Martin; Klingel, Karin; Feghali-Bostwick, Carol; Distler, Oliver; Błyszczuk, Prze-
mysław; Kania, Gabriela (2021). Elevated Fibronectin Levels in Profibrotic CD14+ Monocytes and
CD14+ Macrophages in Systemic Sclerosis. Frontiers in Immunology, 12:642891.
DOI: https://doi.org/10.3389/fimmu.2021.642891
2
Elevated Fibronectin Levels in
Profibrotic CD14+ Monocytes
and CD14+ Macrophages in
Systemic Sclerosis
Michał Rudnik1, Amela Hukara1, Ievgeniia Kocherova1, Suzana Jordan1,
Janine Schniering1, Vincent Milleret2, Martin Ehrbar2, Karin Klingel3,
Carol Feghali-Bostwick4, Oliver Distler1, Przemysław Błyszczuk1,5 and Gabriela Kania1*
1 Department of Rheumatology, Center of Experimental Rheumatology, University Hospital Zurich, University of Zurich, Zurich,
Switzerland, 2 Department of Obstetrics, University Hospital Zurich, Zurich, Switzerland, 3 Department of Molecular Pathology,
University Hospital Tuebingen, Tuebingen, Germany, 4 Division of Rheumatology, Medical University of South Carolina,
Charleston, SC, United States, 5 Department of Clinical Immunology, Jagiellonian University Medical College, Krakow, Poland
Background: Systemic sclerosis (SSc) is an autoimmune disease characterized by
overproduction of extracellular matrix (ECM) and multiorgan fibrosis. Animal studies
pointed to bone marrow-derived cells as a potential source of pathological ECM-
producing cells in immunofibrotic disorders. So far, involvement of monocytes and
macrophages in the fibrogenesis of SSc remains poorly understood.
Methods and Results: Immunohistochemistry analysis showed accumulation of CD14+
monocytes in the collagen-rich areas, as well as increased amount of alpha smooth
muscle actin (aSMA)-positive fibroblasts, CD68+ and mannose-R+ macrophages in the
heart and lungs of SSc patients. The full genome transcriptomics analyses of CD14+ blood
monocytes revealed dysregulation in cytoskeleton rearrangement, ECM remodeling,
including elevated FN1 (gene encoding fibronectin) expression and TGF-b signalling
pathway in SSc patients. In addition, single cell RNA sequencing analysis of tissue-
resident CD14+ pulmonary macrophages demonstrated activated profibrotic signature
with the elevated FN1 expression in SSc patients with interstitial lung disease. Peripheral
blood CD14+ monocytes obtained from either healthy subjects or SSc patients exposed
to profibrotic treatment with profibrotic cytokines TGF-b, IL-4, IL-10, and IL-13 increased
production of type I collagen, fibronectin, and aSMA. In addition, CD14+ monocytes co-
cultured with dermal fibroblasts obtained from SSc patients or healthy individuals acquired
a spindle shape and further enhanced production of profibrotic markers. Pharmacological
blockade of the TGF-b signalling pathway with SD208 (TGF-b receptor type I inhibitor),
SIS3 (Smad3 inhibitor) or (5Z)-7-oxozeaenol (TGF-b-activated kinase 1 inhibitor)
ameliorated fibronectin levels and type I collagen secretion.
Conclusions: Our findings identified activated profibrotic signature with elevated
production of profibrotic fibronectin in CD14+ monocytes and CD14+ pulmonary
macrophages in SSc and highlighted the capability of CD14+ monocytes to acquire a
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profibrotic phenotype. Taking together, tissue-infiltrating CD14+ monocytes/
macrophages can be considered as ECM producers in SSc pathogenesis.
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INTRODUCTION
Systemic sclerosis (SSc) is an autoimmune disease, characterized
by high morbidity and mortality and a significant reduction in
quality of life. Microvascular damages, dysregulation of innate
and adaptive immunity and multiorgan fibrosis are implicated in
the pathophysiology of SSc (1). SSc is characterized by a patient-
to-patient variability in clinical manifestations, autoantibody
profiles, extent of disease, treatment response and reduced
survival rate (2). Changes in internal organ architecture,
leading to pulmonary and cardiac complications and
dysfunction remains the major causes of deaths among SSc
patients (3).
Fibrogenesis is a multistage process, considered as the result
of impaired tissue repair responses, in which abnormal
production of cytokines, growth factors and angiogenic factors
turn tissue homeostasis towards the excessive accumulation of
extracellular matrix (ECM) (4). Fibrosis is usually an outcome
of prolonged and exaggerated activation of fibroblasts, which
differentiate into myofibroblasts (5). In contrast to physiological
wound healing, in which myofibroblast are present only
transiently, in fibrosis myofibroblasts become a permanent
cellular component of the tissue (6).
Myofibroblasts are characterized by expression of alpha
smooth muscle actin (aSMA) forming stress fibers and exhibit
an increased capacity to synthesize collagens, fibronectin, and
other ECM components. Fibronectin is a high-molecular weight
glycoprotein of the extracellular matrix, which binds to integrins
and other extracellular matrix proteins such as collagen, fibrin,
and heparan sulfate proteoglycans (7). Increased deposition of
fibronectin, paralleled to accumulated collagen, has been
reported in the SSc skin (8, 9).
The cellular source of myofibroblasts in wound healing and
fibrotic lesions is still debatable. Although most evidence point to
resident fibroblasts, other tissue-resident cell types or cells
recruited from circulation have been shown to acquire a
myofibroblast-like phenotype (10). In experimental models of
lung and kidney fibrosis, bone marrow-derived fibrocytes have
been shown to be recruited into injured or fibrotic tissues in
response to chemokine signals, where they differentiate into
fibroblasts or myofibroblasts (11). Lineage tracing experiments
have provided convincing evidence that pericytes are an important
source of myofibroblasts during renal fibrogenesis in animal
models, and these cells might also be a source of myofibroblasts
in SSc (12, 13). During fibrogenesis, epithelial cells have been
hypothesized to undergo epithelial-to-mesenchymal transition
and transdifferentiate into myofibroblasts in response to TGFb
and other profibrotic cytokines. Additionally, SSc tissues are
chronically hypoxic, which can further promote the formation
of myofibroblast-like cells (14). In addition to epithelial
cells, endothelial cells have also been hypothesized to
transdifferentiate into myofibroblasts through endothelial-
mesenchymal transition (15).
The primary mechanism underlying excessive fibrosis in SSc
remains unknown; however, TGFb is one of the best-studied
mediators regulating fibrotic processes, including fibroblast
differentiation, ECM deposition and tissue contraction (16).
Elevated levels of TGFb-regulated genes (cartilage oligomeric
matrix protein, thrombospondin-1) were reported in the skin
lesions from SSc patients (17). TGFb signalling regulates the
expression of profibrotic genes mostly via the SMAD-dependent
canonical pathway (18). However, the involvement of several
non-canonical pathways in fibrotic processes was acknowledged.
For example, activation of the ERK-MAPK signalling pathway
leads to upregulation of type I collagen in SSc fibroblasts (19).
Ultimately, inhibition of TGFb signalling has been addressed as a
potential treatment strategy; however, conflicting results were
reported following TGFb blockade (20).
Myeloid cells, including monocytes, have been shown to be
essential regulators of fibrosis as producers of chemokines,
inflammatory cytokines and growth factors (21, 22). Our group
has previously reported that the microenvironment of inflamed
lung induces myeloid progenitors to acquire a myofibroblast
phenotype (23). Similarly, we showed that heart-infiltrating
myeloid cells served as myofibroblast progenitors in the model
of post-inflammatory cardiac fibrosis (24). In the present study,
we evaluated the differentiation potential of circulating CD14+
monocytes from healthy controls and SSc patients into a
myofibroblast-like phenotype.
MATERIAL AND METHODS
SSc Patients and Healthy Controls
Human blood samples and skin biopsies collection were
approved by the local ethics committee of the Canton Zurich
(KEK-ZH 515, PB-2016-02014, KEK-Nr 2018-01873). All study
subjects provided written informed consent. SSc patients and
healthy controls were recruited at the Department of
Rheumatology of University Hospital Zurich. All the patients
fulfilled the ACR/EULAR 2013 classification criteria for SSc.
The patients diagnosed with SSc by experts with Raynaud
syndrome and a least one other SSc characteristic such as: SSc
specific antibodies, SSc characteristic capillaroscopy changes
and/or puffy fingers. The patients not fulfilling the ACR/
EULAR 2013 classification criteria for SSc were grouped as
early-SSc. The patients fulfilling the criteria were further
divided into lcSSc and dcSSc subgroups, according to Le Roy
et al. (25). Detailed demographics and clinical characteristics of
SSc patients are included in Table 1. Healthy control group was
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age- and gender matched (age mean=44.4 ± 10.8, female 17/
20 (85%).
Data are presented as number (n)/total valid cases (N) (%).
Disease duration was calculated as the difference between the
date of the baseline visit and the date of the first non-Raynaud’s
symptom of the disease as reported by the patient. Pulmonary
hypertension was judged on RHC. Active disease was defined as
a score >3 by calculating European Scleroderma Study Group
disease activity indices for systemic sclerosis proposed by
Valentini. Immunosuppressive therapy was defined as
treatment with corticosteroids (prednisone dose ≥10 mg/day or
other dosage forms in equal dose) or any immunosuppressant.
ACA, anti-centromere antibody; ANA, antinuclear antibody;
Anti-Scl-70, anti-topoisomerase antibody; CRP, C reactive
protein; HRCT, computed tomography; DLCO, diffusing
capacity for carbon monoxide; ESR, erythrocyte sedimentation
rate; FEV1, forced expiratory volume in 1 sec; FVC, forced vital
capacity; LVEF, left ventricular ejection fraction; mRSS, modified
Rodnan skin score; NYHA, New York Heart Association; TLC,
total lung capacity; VAI, Valentini activity index.
Human endomyocardial biopsies were provided by the
University Hospital Tubingen, Germany. Samples were
obtained from SSc patients with cardiac involvement
(inflammatory dilated cardiomyopathy) and controls (patients
with healed myocarditis). Lung biopsies were provided by the
Division of Rheumatology, Medical University of South
Carolina, Charleston, USA. The samples were obtained from
SSc-related interstitial lung disease (SSc-ILD). Sample tissue
from downsized lung transplants from healthy individuals
served as controls. The experiments with re-use of human
material were approved by Swissethics (KEK-Nr 2019-00058,
KEK-Nr 2018-01873) and were performed in conformity with
the principles outlined in the Declaration of Helsinki.
Transcriptomic analysis of an already published dataset of
human lung tissues has been included. For this, the University
of Pittsburgh Institutional Review Board approved ethics of use
the human lung samples as previously described (26).
CD14+ Monocytes Isolation
and Differentiation
Blood samples were collected in EDTA tubes (BD Vacutainer)
and processed within 24h. Peripheral blood mononuclear cells
(PBMCs) were isolated by gradient centrifugation on cell
separation medium (Lympholyte, Cedarlane), followed by
magnetic-activated cell sorting for CD14 using human
microbeads and AutoMACS Pro device (Miltenyi Biotec). Cells
were cultured in DMEM low glucose medium (Sigma) with the
addition of 10% Foetal Bovine Serum (FBS) and 1% penicillin/
streptomycin (both Gibco). To differentiate into myofibroblast-
like cells, CD14+ monocytes were stimulated with 10 ng/ml
TGFb (PeproTech), 10 ng/ml IL-4, 10 ng/ml IL-10 and 10 ng/
ml IL-13 (Immunotools) for 7 days.
TABLE 1 | Definitions of items and organ manifestation are according
to EUSTAR.
Baseline demographic and clinical characteristics of the SSc patients
SSc pat (N = 37)
Demographics
Age (mean ± SD) 54.0 ± 14.6
Female sex 32/37 (86.5%)
Disease duration (mean ± SD; years) 14.7 ± 12.5
ACR/EULAR criteria fulfilled 28/37 (75.7%)
Subtype
Diffuse SSc 4/37 (10.8%)
Skin/Vascular
Raynaud’s Phenomenon 32/37 (86.5%)
Digital ulcers 12/37 (32.4%)
Active digital ulcers 3/35 (8.6%)
Pitting scars 11/35 (31.4%)
Scleredema 26/35 (74.2%)
Telangiectasia 20/37 (54.1)
mRSS (mean ± SD) 2.8 ± 4.1
Abnormal nailfoldcapillaroscopy 30/33 (90.6%)
Musculoskeletal
Tendon friction rubs 1/35 (2.9%)
Joint synovitis 5/36 (13.9%)
Joint contractures 9/32 (42.0%)
Muscle weakness 0/31 (0)
Gastrointestinal
Esophageal symptoms 20/37 (54.1%)
Stomach symptoms 8/33 (24.2%)
Intestinal symptoms 14/33 (42.4%)
Cardiopulmonary
Dyspnea
Stage 1 27/34 (79.4%)
Stage 2 5/34 (14.7%)
Stage 3/4 2/34 (5.9%)
Diastolic dysfunction 8/31 (25.8%9
Pericardial effusion 3/24 (12.5%)
Conduction blocks 2/35 (5.7%)
LVEF<45% 0/35 (0)
PAH by RHC 0/37 (0)
Lung fibrosis on HRCT 11/37 (29.7%)
FVC, % predicted (mean ± SD) 93.5 ± 15.4
FVC<70% predicted 1/37 (2.7%)
FEV, % predicted (mean ± SD) 93.2 ± 14.6
TLC, % predicted (mean ± SD) 103.5 ± 16.6
DLCO, % predicted (mean ± SD) 76.0 ± 18.8
DLCO<70% predicted 10/33 (30.3%)
Kidney
Renal crisis 1/37 (2.7%)
Laboratory parameters
ANA positive 37/37 (100%)
ACA 22/37 (59.5%)
Anti-Scl-70 positive 8/36 (22.2%)
Anti-U1RNP positive 0/37 (0)
Anti RNA-polymerase III positive 2/36 (5.5%)
Creatinine kinase elevation 2/27 (7.4%)
Proteinuria 2/35 (5.7%)
Hypocomplementaemia 2/36 (5.5%)
ESR>25 mm/h 9/31 (29.0%)
CRP elevation 5/26 (19.2%)
Active disease (VAI>3) 1/32 (3.1%)
Immunosuppressive therapy 5/37 (13.5%)
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RNA Extraction
Total RNA was isolated using the Quick-RNA Microprep
isolation kit (Zymo Research). Directly after monocyte
treatment, cells were washed with PBS and lysed in RNA lysis
buffer (Zymo Research). An equal volume of absolute ethanol
(Millipore) was added and mixed. Lysates were further processed
on the columns. Genomic DNA was removed by DNase I
treatment. RNA was washed twice and eluted in 10-15 ml of
nuclease-free water (Promega). RNA concentration and purity
were assessed on NanoDrop 1000 (Thermo Fisher Scientific).
Bulk and Single Cell (sc) RNA Sequencing
and Data Analysis
For RNA sequencing, RNA was isolated from SSc patients and
healthy controls [as described previously in Supplementary
Table 1 in (27)] as described above, and RNA Integrity
Number (RIN) was assessed by Tape Station (Agilent).
Samples with RIN≥8 were further processed. RNA sequencing
was performed by the Functional Genomics Centre Zurich. From
100 ng of total RNA, polyA libraries were prepared using the
Illumina TruSeq RNA Stranded mRNA library Kit. Sequencing
was performed on the Illumina HiSeq 4000 platform. Quality of
the sequencing was controlled by FastQC package. Reads were
aligned to the genome using the STAR algorithm. Gene
expression profiles were next calculated by the FeatureCount
algorithm. For differentially expressed genes, the DeSEQ2
algorithm was used with a threshold of minimum 10 reads for
a transcript to be considered as present. Pathway enrichment
analysis of differentially expressed genes (p ≤ 0.01, |log2ratio|
≥0.5) was performed by the Metacore software, as described
previously (27).
Human explanted lung tissues were digested and scRNA-
sequencing was performed as previously described (26).
ScRNAseq Analysis of Each Sample
Raw count matrices produced from CellRanger were loaded from
the dataset GSE128169. Empty droplets were distinguished
from droplet-containing cells by using the emptyDrops
function from the R package DropletUtils (28, 29). Only
droplets that obtained an FDR <= 0.001 were called as cells.
Doublets were also discarded from further analysis using the R
package scDblFinder. Low quality cells were identified based on
the number of reads, genes and mitochondrial content using the
R package scuttle. We excluded cells that were outliers according
to at least one of the following thresholds: number of reads < 3
MADs, number of gene < 3 MADs, mitochondrial content > 3
MADs. Additionally, we discarded genes with < 1 UMI count
in < 0.01 of the remaining cells. We used the SCTransform (30)
method from the R package Seurat (31) to normalize and scale
the data.
Integration of Multiple Samples
Multiple samples were combined using the Seurat integration
workflow (32). After integration we reduced the dimensionality
of the data using Principal Component Analysis (PCA). The
main 30 principal components were used to perfor unsupervised
clustering with a resolution value of 0.8. After clustering and
visualization with Uniform Manifold Approximation and
Projection (UMAP), cell populations were identified through
examination of gene markers in the associated transcriptome.
Cells that had > 0 counts for the CD14 gene were called as
CD14+ cells. All plots and downstream analysis were performed
using Seurat.
RT-qPCR
For reverse transcription, 200-300ng of total RNA was used. The
reaction was performed using MultiScribe reverse transcriptase
(Thermo Fisher Scientific), random hexamers and RNAase
inhibitor (both Roche). Subsequently, the qPCR reaction was
performed using the SYBR green GoTaq qPCR master mix
(Promega) on Agilent Stratagene Mx3005P qPCR instrument.
Sequences of primers are listed in Supplementary Table 1.
Relative gene expression was calculated using the 2-DDCt
method. GAPDH was used as the reference gene.
Protein Extraction and Immunoblotting
After the stimulation with cytokines, cells were washed once with
ice-cold PBS, collected, centrifuged and lysed for 30 minutes on ice
in RIPA buffer (Sigma) supplemented with proteases and
phosphatases inhibitors (Roche). An equal amount of the protein
was loaded and separated by SDS-PAGE electrophoresis, followed
by wet transfer on the nitrocellulose membrane (GE Healthcare).
The membrane was further incubated for 1 hour in blocking buffer
(5% BSA in TBS-T). Further, membranes were probed overnight
with primary antibodies, listed in Supplementary Table 2, in
blocking buffer at 4°C. Further, membranes were incubated for 1
hour at room temperature with secondary HRP-conjugated
antibodies. Signal was developed with ECL substrate (SuperSignal
West Pico PLUS, Thermo Scientific) and acquired on the Fusion fx
(Vilber) device.
ELISA
For the detection of human pro-collagen 1a1 DuoSet ELISA
(RnD Systems) was used according to the manufacturer’s
protocol. Briefly, 96-well plates were coated with capture
antibodies overnight in room temperature and further blocked
with 2% BSA in phosphate-buffered saline (PBS) supplemented
with 0.05%Tween 20. Between each step, plates were washed
three times with PBS. The protein standards and samples were
applied and incubated for 2 hours. Next, plates were incubated
with biotin-conjugated detection antibodies for 2 hours and
streptavidin-HRP for 30 minutes in room temperature. Signal
was developed with TMB substrate (Thermo Scientific), and 450
nm absorbance was measured on a BioTEK HT plate reader
(Tecan). Concentrations were calculated according to the
respective standard curves.
Treatment With Pharmacological Inhibitors
and Cytotoxicity Assessment
SD208 [1 mM], SIS3 [2 mM], (5Z)-7-Oxozeaenol (OXO) [1 mM]
pharmacological inhibitors used in the project were purchased
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from Tocris Biosciences. To determine optimal non-toxic
concentrations, we performed toxicity tests. CD14+ monocytes
were incubated with 2-fold dilutions of inhibitors starting from 5
or 10 µM. Cells were incubated for 24h, stained with propidium
iodide (Biolegend), and cytotoxicity was evaluated by flow
cytometry. The highest non-toxic concentration was used in
further experiments.
2D and 3D Co-Culture With
Dermal Fibroblasts
To distinguish cells in both systems, monocytes were stained
with Cell Trace Violet (Thermo Scientific), and fibroblasts were
stained with CFSE (Biolegend) according to the manufacturer’s
protocol. For 2D co-cultures, fibroblasts were plated 24h prior to
the addition of monocytes. Cells were cultured for 7 days and
sorted using FACSAria III cell sorter.
For the 3D co-culture model, 3DProSeed® hydrogel
microtiter plate (Ectica Technologies) were used. Firstly,
labelled fibroblasts were plated and allowed to penetrate
hydrogels for 24h. Next, monocytes were added. Plates were
incubated for 7 days, and anti-aSMA/phalloidin (both Sigma)




Collected tissue samples were washed in PBS and fixed for 16
hours in 4% paraformaldehyde in PBS. Next, tissues were rinsed
in distilled water and transferred to 50% ethanol. Biopsies were
then dehydrated (three incubations in 80% ethanol for 1 hour,
three incubations in 96% ethanol for 1 hour, two incubations in
100% ethanol for 1 hour). Tissues were cleared twice in xylene
for 1 hour and subsequently incubated twice in a 56°C paraffin
bath for 3 hours. After paraffin embedding, 4 mm thick sections
were placed on Superfrost Plus slides (Thermo Scientific) and
dried overnight. Lung sections were cut at a thickness of 4 mm
and stained with hematoxylin and eosin (HE) for analysis of the
lung architecture and the presence of cellular infiltrates, and with
Picrosirius Red to detect collagen deposition using standard
protocols (33).
For immunohistochemistry sections were deparaffinized in
xylene for 10 minutes (3 times) and rehydrated by sequential
incubations in ethanol solutions (100%, 100%, 96% and 80%) for
3 minutes each. Sections were eventually washed for 5 minutes in
distilled water. Antigen retrieval was performed in citrate buffer
(10 mM citrate, 0.05% Tween, pH=6), and incubated at 95°C for
15 minutes. Endogenous peroxidases were blocked by 3% H2O2
solution for 15 minutes. Unspecific antibody binding was
blocked with 10% goat serum in Background Reducing
Antibody Diluent (Dako). Endogenous biotin was blocked by
Avidin-Biotin Block kit (Vector Laboratories). Sections were
incubated with primary antibodies, listed in the Supplementary
Table 2, in 4°C overnight. The appropriate biotinylated secondary
antibodies (Vector Laboratories) were incubated for 30 minutes at
room temperature, followed by 30 minutes incubation with
VECTASTAIN Elite ABC kit (Vector Laboratories). Staining
was developed using Vector DAB or Vector Red (Vector
Laboratories) followed by a counterstaining of nuclei for 1
minute in Mayer’s hematoxylin solution (J.T Baker). All
sections were mounted using Pertex mounting medium (Dako).
CD14-collagen-1 was performed by Sophistolab AG.
Full slide images were acquired using a Zeiss Axio Scan Z1
slide scanner. ImageJ software was used for relative
quantification of the signal in the sections. For CD45,
mannose-R, CD86, iNOS and arginase-1 staining analysis, the
“HDAB” plug-in was applied, while for Picrosirius Red and a-
SMA “Fast Red, Fast Blue” plug-in was used. Deconvoluted
images were used to calculate the area of the nuclear staining
and the area of the specific signal. The value for each section was
calculated as the ratio of the specific signal to nuclei signal.
Statistical Analysis
Statistical analysis was performed using GraphPad Prism 8
software. Data distribution was calculated using the Shapiro-
Wilk test. Normally distributed data were presented as mean ±
standard deviation and analyzed by unpaired two-tailed
parametric t-test. For non-normally distributed data, unpaired
non-parametric Mann-Whitney U test was used, and medians
were presented. For comparisons of more than two groups, two-
way ANOVA test with multiple comparisons (normally
distributed data) and Kruskal-Wallis test with multiple
comparisons (non-normally distributed data) were used.
Differences were considered statistically significant for p<0.05.
n refers to the number of biological replicates.
Additional methods are described in the SupplementaryMaterial.
RESULTS
Infiltration of CD14+ Monocytes Into the
Organs Co-Localizes With Fibrosis in SSc
In line with data published previously (34), we observed
increased infiltration of CD14+ cells into the heart and lungs of
SSc patients compared to control tissues (Figures 1A, B).
Moreover, CD14 signal co-localized with collagen-rich lesions
in different SSc tissues (Figure 1C). This data suggests that
monocytes may participate in fibrotic processes in many organs
during pathological tissue remodeling in SSc. Furthermore, heart
and lungs of SSc patients showed the increased levels of aSMA+
(myo)fibroblasts, CD68+ pro-inflammatory macrophages and
mannose-R+ (CD206) alternatively activated macrophages
(Figures 2A–C) that reflects inflammatory and fibrotic
microenvironment in different SSc tissues.
Activation of Profibrotic Pathways in
CD14+ Blood Monocytes in SSc
We compared the transcriptome profiles of the total pool of
SSc CD14+ monocytes in relation to CD14+ monocytes obtained
from healthy controls (HC). Pathway analysis revealed
Rudnik et al. Monocyte Differentiation in SSc




FIGURE 1 | Monocyte infiltration into the fibrotic lesion in SSc tissues. (A) Representative images of paraffin-embedded sections of the heart and lungs, and
(B) corresponding quantification of IHC staining for CD14 (lungs HC N=7, SSc N=7, heart HC N=10, SSc N=11, unpaired t-test). (C) Representative images of
paraffin-embedded sections of the heart, lungs and skin co-stained for pro-collagen I (red) and CD14 (brown). (A, C) Scale bar 100mm, scale bar in insert 20mm.
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enrichment of SSc and fibrotic-associated processes, such as
“TGF-beta signalling pathway”, “Toll-like Receptor Signalling
Pathway”, “Angiogenesis” and “VEGF signalling pathway” in SSc
CD14+ monocytes (Figure 3A). At the transcription level, we
observed dysregulated expression of essential profibrotic
genes: TGFBR2, MMP9, JUN, COL9A3, COL18A1, FN1 and
WNT5B (Figures 3B, C). Further, we demonstrated that
SSc CD14++CD16- monocyte population showed significantly
higher FN1 expression than SSc CD14+CD16+ and
CD14lowCD16+ monocyte populations (Figure 3D). Of note, we
did not notice any difference in FN1 expression between these three
monocyte populations in HC monocytes (Figure 3D). Importantly,
SSc CD14++CD16- and CD14+CD16+ monocyte populations
revealed profibrotic features by expressing upregulated FN1 levels
compared to HC monocytes (Figure 3D).
This result indicated an activated, profibrotic phenotype of
SSc CD14+monocytes in the circulation, which might predispose




FIGURE 2 | Characteristic of human SSc lung and heart tissues. Representative images of paraffin-embedded sections of the heart and lungs and corresponding
quantification of IHC staining for aSMA (A), CD68 (B) and mannose-R (CD206) (C) (lung HC N=7, lung SSc N=7, heart HC N=10, heart SSc N=11, unpaired t-test;
scale bar 100mm, scale bar in insert 20mm).
Rudnik et al. Monocyte Differentiation in SSc
Frontiers in Immunology | www.frontiersin.org August 2021 | Volume 12 | Article 6428917
Activation of Profibrotic Pathways in
CD14+ Pulmonary Macrophages in SSc
Transcriptomic analysis of an already published dataset of lung tissue
from 4 HC and 4 SSc-ILD patients has been performed (26). CD14+
cells were visualized in all macrophage clusters (FCN1hi, SPP1hi,
FABP4hi and proliferating macrophages) (Figure 4A), determined as
previously shown (26). Pathway analysis revealed enrichment of
fibrosis-associated processes, such as “Extracellular matrix
disassembly”, “Extracellular matrix organization”, “Cellular response
to cytokine stimulus” and “Cytokine-mediated signalling pathway” in
SSc CD14+ cells (Figure 4B). At the transcription level, we noticed
upregulation expression of several profibrotic genes, including
TGFb1, TIPM1, TIPM2, FN1 and ADAM10 (Figure 4C).
Importantly, in all macrophage clusters in SSc lungs, we observed
upregulated expression of FN1 in CD14+ cells (Figures 4D, E).
Profibrotic Cytokine Stimulation Induces
Differentiation of Monocytes Into
Myofibroblast-Like Cells
Bonemarrow-derived cells have been proposed as one of the sources of
myofibroblasts. Therefore, next, we evaluated the potential of CD14+
monocytes to differentiate into myofibroblast-like cells in response to
profibrotic stimulationwith TGFb, IL-4, IL-10 and IL-13 cytokines.We
observed the induction of profibrotic gene expression including
ACTA2, COL1A1 and FN1 (Figure 5A). Additionally, stimulated




FIGURE 3 | Transcriptomic analysis of CD14+ monocytes from SSc patients and HC. (A) Pathway enrichment analysis of SSc-related biological processes
calculated based on differentially expressed gene sets (Metacore software). (B) Differentially expressed genes involved in fibrosis from RNAseq data. (C) qPCR
confirmatory analyses of selected genes from RNAseq data (N=5-20, Mann Whitney-U-test). (D) qPCR analysis of FN1 mRNA levels in sorted CD14++CD16-,
CD14lowCD16+ and CD14+CD16+ monocyte from SSc patients and HC (n=3-6, Mann Whitney-U-test).
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and fibronectin (Figures 5B, C). Time-dependent profibrotic
stimulation with TGFb, IL-4, IL-10 and IL-13 cytokines revealed that
CD14+ monocytes upregulated profibrotic gene expression already
after 24h and sustain these levels up to 7 days (Figure 5D). Of note, we
did not observe any difference in the differentiation potential between






FIGURE 4 | Characteristic of CD14+ macrophages in SSc-ILD lung tissues. Four human healthy control (HC) and 4 SSc-ILD lung tissue samples were used for a
single-cell (sc) RNA-sequencing analysis according to Valenzi et al. (26). (A) UMAP plot visualization of CD14+ cells in macrophage clusters in HC and SSc-ILD
samples. (B) Pathway expression in the specific GO biological process (Enrichr 2018) and the expression of selected fibrotic-related genes (C) upregulated in SSc-
ILD CD14+fibronectin (FN1)+ cells compared to HC CD14+ cells in lungs. (D) FN1 expression in SSc-ILD CD14+ cells compared to HC CD14+ cells in lungs (N=4,
Mann Whitney-U-test). (E) UMAP plot visualization of CD14+ cells in macrophage clusters in HC and SSc-ILD samples. UMAP, uniform manifold approximation and
projection; SSc-ILD, systemic sclerosis-associated interstitial lung disease.
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Co-Culture With Dermal Fibroblasts
Enhances Profibrotic Phenotype of
CD14+ Monocytes
We hypothesized that the microenvironment might play a
determinant role in the profibrotic response of CD14+
monocytes. To test this hypothesis, we co-cultured CD14+
monocytes with side-matched dermal fibroblast from SSc
patients and HCs for 7 days. To analyze gene expression, cell
types were separated using FACS sorting. We observed that co-
culture with dermal fibroblasts induced expression of profibrotic
genes ACTA2, COL1A1 and FN1 in both HC and SSc monocytes.
Importantly, we noticed a significant induction of gene
expression by SSc fibroblasts (Figure 6A).
Further, we aimed to observe phenotypic changes of CD14+
monocytes after co-cultures in 2D and 3D models. Monocytes,
which were sorted out after the 2D co-culture and re-plated in a
chamber slide, were stained with phalloidin and anti-aSMA




FIGURE 5 | Profibrotic stimulation induces differentiation of monocytes into fibroblast-like cells. (A) mRNA expression of COL1A1, ACTA2 and FN1 after profibrotic
cytokines stimulation (TGFb, IL-4, IL-10, IL-13 [10 ng/ml each]) of HC and SSc monocytes (N=13, two-way ANOVA with Benjamini, Krieger and Yekutieli post-hoc
test). (B) ELISA measurement of Pro-collagen 1a1 concentration in supernatants from CD14+ monocytes after profibrotic cytokines stimulation (TGFb, IL-4, IL-10, IL-
13, [10 ng/ml each]) (N=13, two-way ANOVA with Benjamini, Krieger and Yekutieli post-hoc test). (C) Western blot assessment of fibronectin level in cell lysates and
supernatants from CD14+ monocytes stimulated with profibrotic cytokines (TGFb, IL-4, IL-10, IL-13, [10 ng/ml each]) (N=3). (D) Time-dependent mRNA expression
of COL1A1, ACTA2 and FN1 after profibrotic cytokines stimulation (TGFb, IL-4, IL-10, IL-13 [10 ng/ml each]) of HC monocytes at following time points: 0, 8, 24, 47,
72 and 168h (N=4, two-way ANOVA with Tukey’s multiple comparison test, p values for row factor).
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the co-culture acquired spindle shape, however, they failed to
form stress fibers (Figure 6B). Similar characteristics were
observed for monocytes in 3D co-culture (Figure 6C). Taken
together, the fibroblast microenvironment induced a change





FIGURE 6 | Profibrotic microenvironment induces differentiation of monocytes into fibroblast-like cells. (A) mRNA expression of ACTA2, COL1A1 and FN1 in CD14+
monocytes from HC and SSc patients after co-culture with HC and SSc skin fibroblasts (HC N=5, SSc N=6, two-way ANOVA with Uncorrected Fischer’s LSD post-
hoc test, **p < 0.005). (B) Representative images of immunofluorescence staining of CD14+ monocytes with and without co-culture with fibroblasts (blue– DAPI
nuclear staining, red– Phalloidin staining, green- a-SMA staining). (C) Representative images of immunofluorescence staining of HC and SSc CD14+ monocytes co-
cultured with fibroblasts in 3D hydrogel model (blue– monocytes stained with Cell Trace Violet, green– fibroblasts stained with CFSE, red– a-SMA staining, grey-
Phalloidin staining). ns, not significant.
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TGFb Is a Key Regulator of Profibrotic
Gene Expression in Monocyte-Derived
Myofibroblast-Like Cells
Fibrotic processes might be driven by various stimuli; however,
TGFb is regarded as a pivotal mediator during SSc. To analyze
the role of TGFb signalling in monocyte-to-myofibroblast-like
cell differentiation, we inhibited selected TGFb downstream
pathways in CD14+ monocytes treated with the profibrotic
cytokine cocktail (TGFb, IL-4, IL-10 and IL-13). Treatment
with the TGFBR1 kinase inhibitor SD-208 completely
abolished expression of the ECM components collagen 1 and
fibronectin on both mRNA and protein levels (Figure 7).
Interestingly, TGFb-induced expression of COL1A1 was
suppressed by the inhibitor of canonical SMAD-dependent
pathway SIS3, but not by inhibition of TAK1-dependent non-
canonical pathway with 5z-7-oxozeaenol (OXO). On the other
hand, blocking of canonical and non-canonical TGFb
downstream pathways was sufficient to decrease expression
and secretion of fibronectin (Figure 7B).
DISCUSSION
Our data demonstrated that human peripheral blood circulating
CD14+ monocytes exhibited profibrotic phenotype in SSc
patients. Similarly, several reports indicated fibroblast-like/
circulating Collagen I-producing CD14+ monocytes or CD14-
fibrocytes as profibrotic cell progeny in SSc (35). Likewise, the
alternatively activated macrophages derived from circulating
CD14+ monocytes have also been considered as profibrotic
cells in SSc (36). SSc patients have higher levels of circulating
CD34+CD14+ cells, Collagen-I-producing CD14+ monocytes
and CD163+ monocytes (36). Importantly, monocyte count
could be incorporated into the clinical assessment of patients
with fibro-proliferative disorders (37), including SSc patients
with interstitial lung disease (ILD). Accordingly, the elevated
numbers of Collagen-I-producing fibrocytes and profibrotic
monocytes in SSc patients were associated with ILD
progression and implicated in the pathogenesis of SSc-ILD
(36). Circulating Collagen-I-producing fibrocytes have also
been coupled with a growing repertoire of human diseases
A
B
FIGURE 7 | Monocyte-to-fibroblast-like cells differentiation is dependent on TGFb signalling pathways. (A) COL1A1 mRNA expression level and ELISA
measurements of Pro-collagen 1a1 protein level in supernatants after profibrotic cytokine stimulation (TGFb, IL-4, IL-10, IL-13 [10 ng/ml each]) and treated with
TGFb signalling pathway inhibitors [SD208 and (5Z)-7-Oxozeaenol (OXO) 1 mM, SIS3 2 mM] (N=4-7, one-way ANOVA with Benjamini, Krieger and Yekutieli post-hoc
test). (B) FN1 mRNA expression level and Western Blot analysis, and corresponding densitometry of Fibronectin protein level in the supernatants after profibrotic
cytokine stimulation (TGFb, IL-4, IL-10, IL-13 [10 ng/ml each]) and treated with TGFb signalling pathway inhibitors [SD208 and (5Z)-7-Oxozeaenol (OXO) 1 mM, SIS3
2 mM] (N=4-7, one-way ANOVA with Benjamini, Krieger and Yekutieli post-hoc test).
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including renal fibrosis (38), cirrhosis (39), nephrogenic systemic
fibrosis (40), pulmonary fibrosis (41–43), and asthma (44).
It has been reported that the fibronectin splice variant-
fibronectin extra domain A (FnEDA) is an endogenous TLR4
ligand. Importantly, elevated levels of FnEDA were
demonstrated in the serum and skin lesions from SSc patients
and in mouse model of cutaneous fibrosis (45). In chronic
inflammatory diseases and during the healing phase of acute
inflammatory reactions, the alternatively activated M(IL-4)
macrophages showed significantly upregulated levels of
fibronectin that suggest an active role of fibronectin+
macrophages in the ECM deposition and tissue remodeling
(46). Furthermore, the alveolar macrophages from lungs of
SSc-ILD patients displayed elevated levels of fibronectin (47).
These reports are in line with our results, which presented the
elevated fibronectin levels in circulating CD14+ monocytes and
CD14+ pulmonary macrophages in SSc patients and highlighted
the capability of CD14+ monocytes to acquire a profibrotic
phenotype. Of note, monocyte-to-macrophage differentiation
has been linked with the increase production of fibronectin
(48). We, therefore, concluded that tissue-infiltrating CD14+
monocytes/macrophages can be considered as ECM producers
in the pathogenesis of fibrosis in SSc. All these data point to
fibronectin as a potential target in therapeutic strategy in SSc.
Monocyte infiltration into the tissue affects the initiation of
fibrotic processes in the skin and internal organs in SSc (49–51).
Our data clearly presented infiltrating CD14+ monocytes in the
collagen-rich area in SSc-ILD lungs, myocardium of SSc patients
with inflammatory dilated cardiomyopathy (iDCM) and in
SSc skin (27). Increased numbers of spindle-shaped
CD14+CD34+collagen-I+ cells were found in the lungs of SSc-
ILD patients (36). The bone marrow origin of fibroblasts or
myofibroblasts in different tissues under homeostasis and disease
condition has been debatable for many years now. In vivo data,
with the use of cutaneous wound mouse model, confirmed that at
least a part (15%-20%) of the spindle-shaped dermal fibroblasts
were bone marrow origin (52). In contrast, another report
suggested that bone marrow-derived progenitors contributed
to the inflammatory cell pool infiltrating the wound area;
however, they did not differentiate into dermal (myo)
fibroblasts at the wound site (53, 54). In the bleomycin-
induced skin fibrosis model, a significant number of CD45-
positive collagen-producing cells of bone marrow origin
contributed to collagen production during dermal fibrogenesis
but not under homeostasis, indicating bone marrow originated
cells as a cell source for (myo)fibroblasts under disease condition
(55). Similarly, in bleomycin-induced lung fibrosis mouse model
bone marrow-derived progenitors gave rise to collagen-
producing cells but not to aSMA+ myofiboblasts in the
inflamed/fibrotic lungs (56, 57). Oppositely, in the renal
fibrosis the inflammatory macrophages, characterized by
alternatively activated macrophage markers, acquired fibroblast
phenotype by collagen I and aSMA expression and actively
contributed to the fibrogenesis (58).
Nevertheless, the transition of bone marrow-derived
monocytes or macrophages (mainly alternatively activated
macrophages) into functional myofibroblasts has been
mediated by canonical SMAD2/3-dependent or non-canonical
TAK-1-dependent TGFb signal (24, 59–61). Accordingly, our
results confirmed that both canonical and non-canonical TGFb
pathways were important to obtain the fibroblast-like phenotype
of circulating CD14+ monocytes, indicating the broad
treatment options.
The pathophysiology of SSc is closely related to the activated
TGFb-dependent pathway. The levels of a latent, not-active form
of TGFb is similar in SSc and healthy serum samples. Active
TGFb serum levels were significantly higher in SSc, mainly in
dcSSc, patients and correlated with clinical manifestations
(digital ulcers, lung fibrosis, positive antitopoisomerase I and
higher modified Rodnan score) (62). These results indicate TGFb
as a potential marker of fibrotic and vascular involvement in SSc
on one side, and on the other side, it reflects an altered
microenvironment, which may predispose circulating
monocytes towards an activated and profibrotic phenotype.
Accordingly, we used this cytokine, among others, to activate
circulating monocytes towards a profibrotic phenotype. As
expected, CD14+ monocytes stimulated with TGFb, IL-4, IL-10
and IL-13 or co-cultured in 2D and 3D model with human
dermal fibroblasts were able to adopt a functional myofibroblast-
like phenotype that may indicate these cells as one of the cellular
sources of profibrotic cells upon their entrance into the tissues.
The previous report indeed showed that GM-CSF, IL-4 and
endothelin-1 alone or in combination induced myofibroblast-
like differentiation of circulating SSc and healthy monocytes (63).
Additionally, the profibrotic phenotype of circulating CD14+
monocytes from SSc-ILD patients was confirmed by the
expression of CD163 and boosted secretion of CCL18 and IL-
10 in response to pro-inflammatory stimuli (36). However, as in
our stimulation conditions, monocytes from SSc patients showed
no differences in acquiring more pronounced profibrotic
phenotype compared to monocytes from healthy donors.
Therefore, we assume that under inflammatory conditions (i.e.
in SSc) more circulating already activated monocytes are
recruited to the injury site, where they play a profibrotic role,
either by the transition into fibroblast-like cells or by the
production of profibrotic stimuli. In line with this hypothesis,
Bhandari et al. demonstrated that soluble factors in the local
milieu are crucial for pro-fibrotic activation of SSc macrophages
(measured as secretion of CCL2, IL-6, TGFb), arisen from
circulating monocytes either stimulated with SSc sera or
conditioned media from indirect co-culture with dermal SSc
fibroblasts (64). These results point to monocytes and monocyte-
derived macrophages as probable key players in fibrogenesis in
SSc, suggesting targeted cell therapeutic options as feasible and
favorable in SSc.
Besides a known and active role of IL-6 and TGF-b signalling
in the pathogenesis of SSc, there is increasing evidence that also
Th-2 cytokines: IL-4 and IL-13, are involved in the pathology of
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SSc (65, 66). Both cytokines relate to profibrotic responses,
including connection with increased expression of novel
myofibroblast marker: periostin, a matricellular protein
important in fibrogenesis (67). Based on our data, the
combination of TGFb, IL-4, IL-10 and IL-13 was sufficient to
obtain a fibroblast-like phenotype by circulating CD14+
monocytes, indicating that IL-4/IL-13 targeted therapy might
be an attractive option against fibrogenesis in SSc (68). Indeed, a
randomized, double-blind, placebo-controlled, 24-week, phase
II, proof-of-concept study (trial registration number:
NCT02921971) with romilkimab (a bispecific immunoglobulin-
G4 antibody that binds and neutralizes IL-4/IL-13; SAR156597)
in early dcSSc patients revealed a beneficial effect of this treatment
on skin disease changes, i.e. statistically significant decrease in mRSS
from baseline to week 24 versus placebo (69).
Given the alerted activation status of circulating CD14+
monocytes and their ability to accumulate in the affected
organs in SSc, we believe that further research should focus on
finding even more targeted therapies, which may invert the
activation status of monocytes in the circulation.
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